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CORRESPONDENCE
Re: The use and impact of
national confidential enquiries
in high-income countries
BMJ Qual Saf 2011;20:38e45
Angelow and Black1 mount a series of
scathing criticisms of the national confi-
dential enquiries (NCEs). They suggest
‘nesting’ NCEs within prospective National
Clinical Audits. The competing interest
declared by one of the authors is that he
chairs the National Clinical Audit Advisory
Group. He was also a member of the group
convened by the National Patient Safety
Agency (NPSA) that advised on the future
of the NCEs.
The criticisms are without merit, and I
deal with them in turn.
First, it is alleged that the research
evidence of the impact of the recommen-
dations is poor, with no time series analysis
or experimental studies and is restricted to
considering their impact on the structure
and process rather than the outcome of care.
The role of the NCE is to enable the
profession to describe the gap between what
is happening to selected groups of patients
and what it believes should happen, to
suggest improvements and to propagate
those suggestions. The undoubted value of
audit does not denigrate the value of
detailed observational studies. Neither time
series analyses nor experimental studies are
relevant to assess the impact of what is best
seen as a means by which the profession is
able to learn from its own experience.
The National Confidential Enquiry into
Patient Outcome and Death (NCEPOD)
does not depend upon demonstration of
cause and effect, and therefore the argu-
ment that we are vulnerable to compounding
factors and the dangers of hindsight is also
irrelevant. When we looked at a sample of
those who died within 30 days of starting
systemic anticancer therapy, what mattered
was not the discovery that the experts
thought that death was attributable to the
therapy rather than the disease in a large
minority of cases; what mattered far more
was that only 35% of patients received care
that the advisors would accept from their
own teams or their own institutions.2
These are the views of mainstream profes-
sionals rather than hot-headed enthusiasts.
They identified specific improvements
which were immediately welcomed by the
cancer tsar and the rest of the profession.
The National Chemotherapy Advisory
Group set out a series of recommendations
to address these concerns, which were said
by the DH in their Outcomes Strategy for
Cancer in January 2011 to remain highly
relevant and suitable for use in developing
quality standards.
Similar impact could be demonstrated in
respect of recent studies into parenteral
nutrition, acute kidney injury, sickle-cell
disease and now surgery in older people.
The authors make no reference to the
citation indices of the NCEPOD reports, the
clinical impact they have in the guidelines
changed or the extent to which the studies
have been replicated by the application of
our toolkits which, like our reports, are all
available free of charge from the NCEPOD
website.
Second, they question the validity of
recommendations in the reports. The
principal example cited arises from
another before and after study conducted
in a single hospital which looked at the
impact of a NCEPOD recommendation
that patients with a fractured femur should
undergo pre-operative echocardiography
claimed that this harmed patient care by
increasing the incidence of operative
delays of 3e10 days from 14% to 21%
(though not statistically significant given
the small study size).
In 2001, NCEPOD authors extrapolated
that more than 200 patients a year were
dying of undiagnosed aortic stenosis or
other cardiac disease in the course of non-
cardiac surgery. They suggested that an
asymptomatic cardiac murmur should be
investigated preoperatively by echocardiog-
raphy. There was no proposal to subject all
fractured femurs to echo. The report
recognised that echo services were under
pressure and called for proper resourcing.
The article referenced by the authors
found that at Haywards Heath, in four cases,
it took 4e10 days to organise an echo and
suggested that clinicians should exercise
their own judgement where it would involve
a preoperative delay of >48 h. NCEPOD
would hardly have disagreed since one of
its principal recommendations then, as
repeated in the recent study into surgery in
older people, was that treatment of frac-
tured neck of femur should not be delayed.
Over the following years, the profession
agreed that surgical teams should investi-
gate incidental signs of cardiac abnormality
more actively, and in most places echo
services improved to support them. The
picture varies because there are still no
nationally accepted indications for echod
in most places, recommendations regarding
the advice about which murmurs should
undergo evaluation have been refined. Far
from indicating that NCEPOD’s recom-
mendations were invalid, this episode shows
how two suggestions have changed practice.
In the recent study An Age Old Problem, cases
studied in 2008 described no deaths from
undiagnosed aortic stenosis.3
Third, the most worrying criticism was the
concern about the lack of information on
the cost benefit of NCEs was recognised by
the major funder of NCEs in England and
Wales in 2007.
The reference given is the minutes of
a board meeting of the NPSA in March
2007. That board meeting received the
NPSA’s own detailed review of NCEPOD’s
work, which included among numerous
other favourable comments:
At approximately £0.5m per study, the
panel considered that NCEPOD provided
remarkably good value for money but
question whether this could be sustained.
Incidentally, the authors failed to refer-
ence similarly favourable external reviews
of NCEPOD’s standing and impact carried
out by the National Institute for Clinical
Excellence in 2004 and a reputation audit
by Opinion Leader Research in 2006. The
latter praised our methodology and reported
that recommendations often led to action
by NHS trust boards because we are seen as
independent.
NCEPOD’s grant has been reduced so
that we will now have £250 000 per study in
future. It would be unfortunate if in fact this
reduction was triggered by incorrect advice
to the DH about costebenefit.
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Authors’ response
As with all approaches to assessing and
improving the quality of healthcare, it is
important that we establish, as rigorously as
possible, their impact and cost-effectiveness.
Just as we rightly expect healthcare practice
and policy to be informed by research
evidence, we should expect the same for
quality assessment and improvement activi-
ties that consume resources that could
otherwise be spent on care. Without
rigorous evaluation, we cannot know how
best to improve the quality of healthcare.
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With this goal in mind, we undertook
a long overdue review of the research
evidence of the impact of national confi-
dential enquiries (NCEs), an approach to
assessing the safety of care that has changed
little since its inception about 50 years ago.
We concluded by pointing out the need for
more rigorous evaluation of NCEs and
suggested that the value of NCEs might be
enhanced by conceiving them as comple-
mentary to prospective national clinical
audits.1 Mr Leigh seems to have viewed
these recommendations as threats rather
than as ways of strengthening the value of
NCEs.2
Mr Leigh argues that rigorous evaluative
methods are not needed or appropriate
when considering the impact of NCEs. He
writes that the National Confidential
Enquiry into Patient Outcome and Death
(NCEPOD) ‘does not depend upon
demonstration of cause and effect’ so that
neither ‘time-series analyses nor experi-
mental studies are relevant to assess the
impact of what is best seen as a means by
which the profession is able to learn from its
own experience.’ While clinicians’ beliefs
and opinions were seen as sufficient
evidence of the benefits of healthcare
activities in the past, this is no longer
deemed adequate by the public, policy-
makers, managers and most clinicians.
Thus, his claim that NCEPOD is not
‘vulnerable to compounding [sic] factors
and the dangers of hindsight’ is a bold
assertion that needs to be demonstrated
before it could be accepted. It is highly
unlikely that the apparent impact of an
NCE is not vulnerable to confounding or
reporting bias.
Mr Leigh was also concerned that we
questioned the validity of recommendations
based on the findings of NCEs. The basis of
our view is that as an NCE is a case series, it
cannot establish causality, and therefore
great care should be exercised in drawing
conclusions as to how policy or practice
should change. The value of a case series
lies in generating hypotheses that then
need to be tested using analytical methods
(case-control, cohortdincluding time-
seriesdor experimental designs) to estab-
lish both causality and the strength of any
observed relationships. Only then can
recommendations for practice and policy
be made with any confidence.
The lack of any published studies of the
impact of NCE recommendations on the
outcome of care means that there is no
rigorous evidence as to the validity of such
recommendations. The nearest to such an
example is the study we cited by Guryel
et al.3 In that study, the authors suggest
that a recommendation from NCEPOD to
perform echocardiography before surgery,
in patients suspected of having aortic
stenosis, was associated with an increase in
the proportion of patients experiencing an
operative delay (of 3e10 days) from 14% to
26%. Although this was a small study in one
hospital, it illustrates that unintended
consequences may occur and underlines
the urgent need for definitive evaluations of
the impact of recommendations derived
from NCEs.
Finally, Mr Leigh criticises our ques-
tioning of the costebenefit of NCEs as
unwarranted and states that this has not
been a concern of the National Patient
Safety Agency (NPSA) in England. To
support our claim, we cited the minutes of
the NPSA Board for January 2007 when
the conclusions of a review of the Confi-
dential Enquiry into Maternal & Child
Health (CEMACH) were accepted. That
review noted that ‘without any cost v
benefit analysis [the NPSA] were less able to
assess its value in terms of cost’ and
concluded that ‘there is a need to provide
cost benefit analysis both in terms of
implementation and non-implementation
for the NHS in terms of clinical outcomes
and patient safety. CEMACH must prove
value for money.’. We agree with NPSA
and feel this is consistent with the research
evidence.
We were aware of external reviews such as
those carried out by NICE and Opinion
Leader Research that offered supportive
opinions of NCEs, but, as we made clear, we
confined our review to scientific evaluations
in peer-reviewed journals.
Given the range of approaches available
for assessing and improving the quality of
healthcare, it’s essential that opportunity
costs are considered and that the limited
resources available support the most
cost-effective activities. This can only be
achieved if everyone committed to
enhancing quality accepts the need for
rigorous evaluation to inform the best
ways of organising and managing quality
assessment and improvement.
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